(Q35792937)

10 August 2017

1 reference

title

Efficacy and safety of a Haemophilus influenzae type b capsular polysaccharide-tetanus protein conjugate vaccine (English)

1 reference

10 August 2017

1 reference

Haemophilus influenzae

object named as

Haemophilus influenzae

1 reference

B. Fritzell

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1517908

4 October 2022

S. Plotkin

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1517908

4 October 2022

language of work or name

English

0 references

publication date

1 September 1992

1 reference

The Journal of Pediatrics

10 August 2017

published in

1 reference

10 August 2017

volume

121

1 reference

10 August 2017

issue

3

1 reference

10 August 2017

page(s)

355-362

1 reference

Lack of efficacy of Haemophilus b polysaccharide vaccine in Minnesota

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981786-X

Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981786-X

A randomized, prospective field trial of a conjugate vaccine in the protection of infants and young children against invasive Haemophilus influenzae type b disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981786-X

Limited efficacy of a Haemophilus influenzae type b conjugate vaccine in Alaska Native infants. The Alaska H. influenzae Vaccine Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981786-X

Efficacy in infancy of oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine in a United States population of 61,080 children. The Northern California Kaiser Permanente Vaccine Study Center Pediatrics Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981786-X

The efficacy in Navajo infants of a conjugate vaccine consisting of Haemophilus influenzae type b polysaccharide and Neisseria meningitidis outer-membrane protein complex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981786-X

Variability in the functional activity of vaccine-induced antibody to Haemophilus influenzae type b

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981786-X

Comparative trial in infants of four conjugate Haemophilus influenzae type b vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981786-X

The epidemiology and prevention of disease caused by Haemophilus influenzae type b.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981786-X

Quantitative measurement of "natural" and immunization-induced Haemophilus influenzae type b capsular polysaccharide antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981786-X

Comparison of active and combined passive/active immunization of Navajo children against Haemophilus influenzae type b.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981786-X

Passive immunization against disease due to Haemophilus influenzae type b: concentrations of antibody to capsular polysaccharide in high-risk children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981786-X

The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981786-X

Immunogenicity and safety of PRP-T conjugate vaccine given according to the British accelerated immunisation schedule

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981786-X

Clinical and immunologic responses to Haemophilus influenzae type b-tetanus toxoid conjugate vaccine in infants injected at 3, 5, 7, and 18 months of age

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981786-X

Impact of Haemophilus influenzae Type b Polysaccharide-Tetanus Protein Conjugate Vaccine on Responses to Concurrently Administered Diphtheria-Tetanus-Pertussis Vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981786-X

Reduction of oropharyngeal carriage of Haemophilus influenzae type b (Hib) in children immunized with an Hib conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981786-X

Further studies on the immunogenicity of Haemophilus influenzae type b and pneumococcal type 6A polysaccharide-protein conjugates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981786-X

inferred from DOI database lookup

7 January 2021

based on heuristic

Serum antibody responses of juvenile and infant rhesus monkeys injected with Haemophilus influenzae type b and pneumococcus type 6A capsular polysaccharide-protein conjugates

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981786-X

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0022-3476(05)81786-X

1 reference

10 August 2017

1 reference